Literature DB >> 33748697

Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19.

Immacolata Andolfo1,2, Roberta Russo1,2, Vito Alessandro Lasorsa1,2, Sueva Cantalupo1,2, Barbara Eleni Rosato1,2, Ferdinando Bonfiglio3, Giulia Frisso1,2, Pasquale Abete4, Gian Marco Cassese4, Giuseppe Servillo5, Gabriella Esposito1,2, Ivan Gentile6, Carmelo Piscopo7, Romolo Villani8, Giuseppe Fiorentino9, Pellegrino Cerino10, Carlo Buonerba10, Biancamaria Pierri10,11, Massimo Zollo1,2, Achille Iolascon1,2, Mario Capasso1,2.   

Abstract

The established risk factors of coronavirus disease 2019 (COVID-19) are advanced age, male sex, and comorbidities, but they do not fully explain the wide spectrum of disease manifestations. Genetic factors implicated in the host antiviral response provide for novel insights into its pathogenesis. We performed an in-depth genetic analysis of chromosome 21 exploiting the genome-wide association study data, including 6,406 individuals hospitalized for COVID-19 and 902,088 controls with European genetic ancestry from the COVID-19 Host Genetics Initiative. We found that five single nucleotide polymorphisms within TMPRSS2 and near MX1 gene show associations with severe COVID-19. The minor alleles of the five single nucleotide polymorphisms (SNPs) correlated with a reduced risk of developing severe COVID-19 and high level of MX1 expression in blood. Our findings demonstrate that host genetic factors can influence the different clinical presentations of COVID-19 and that MX1 could be a potential therapeutic target.
© 2021 The Authors.

Entities:  

Keywords:  Genetics; Genomics

Year:  2021        PMID: 33748697      PMCID: PMC7968217          DOI: 10.1016/j.isci.2021.102322

Source DB:  PubMed          Journal:  iScience        ISSN: 2589-0042


Introduction

The recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused so far more than over 2.5 million deaths (https://covid19.who.int/). The coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2, is associated with diverse clinical presentations, ranging from asymptomatic or mildly symptomatic infections to respiratory failure and death (Bellani et al., 2021; Grasselli et al., 2020, 2021; Richardson et al., 2020). Advanced age is an established risk factor, as well as male sex and comorbidities such as hypertension and diabetes (Zhou et al., 2020). Since these risk factors do not fully explain the wide spectrum of disease manifestations, dissecting the genetics of the host response to SARS-CoV-2 infection may provide novel insights into its pathogenesis (Anastassopoulou et al., 2020). A genome-wide association study (GWAS) (Ellinghaus et al., 2020) identified two susceptibility loci of severe COVID-19: the first locus on chromosome 3 harbors multiple genes (SLC6A20, LZFTL1, CCR9, CXCR6, XCR1, FYCO1) that could be functionally implicated in COVID-19 pathology; the second on chromosome 9 that defines the ABO blood groups (Ellinghaus et al., 2020). Other very recent papers reported the results from the analysis of two large independent GWASs that validated the two previous risk loci and found novel risk variants at chromosome 19p13.3, 12q24.13, and 21q22.1 associated with severe COVID-19 (Pairo-Castineira et al., 2021; Shelton et al., 2020). Two whole-exome sequencing studies showed that inactivating rare mutations in genes belonging to the type I interferon pathway predispose to life-threatening COVID-19 pneumonia (van der Made et al., 2020; Zhang et al., 2020). Additionally, preliminary results on a small set of Italian cases suggest that coding variants in TMPRSS2 and PCSK3 may contribute to the variability in infection susceptibility and severity (Latini et al., 2020). In our previous opinion article, based on the analysis of allele frequencies across different populations and expression quantitative trait loci (eQTLs) data, we hypothesized that common variants on chromosome 21 near TMPRSS2 and MX1 genes may be genetic risk factors associated with the COVID-19 different clinical manifestations (Russo et al., 2020). Both TMPRSS2 and MX1 are involved in the host response to SARS-CoV-2 infection. ACE2 is the main entry receptor for SARS-CoV-2 (Wang et al., 2020). Entry depends on the binding of the surface unit S1 of the spike (S) protein of the virus to the receptor. SARS-CoV-2 engages ACE2 as the entry receptor and employs the host cellular TMPRSS2 for S-protein priming (Hoffmann et al., 2020b; Matsuyama et al., 2010). Particularly, binding of SARS-CoV-2 S-protein with ACE2 receptor is then followed by host TMPRSS2-mediated cleavage of the viral S-protein. This process, defined as priming, involves cleavage of the S-protein at S1/S2 and S2 sites which is essential for the viral fusion with the host cell membrane before entry into the cell (Hoffmann et al., 2020b; Matsuyama et al., 2020). SARS-CoV-2 can use other proteases such as cathepsin B/L for S-protein in the absence of TMPRSS2 receptors. However, in the lungs (the primary organ for SARS-CoV-2 infection), cathepsin B/L cannot substitute for TMPRSS2 protease activity as the latter is indispensable for viral entry as observed for SARS-CoV and MERS-CoV (Hoffmann et al., 2020a). MX1 is an interferon-α/β inducible gene that encodes a guanosine triphosphate metabolizing protein involved in the cellular antiviral response (Ciancanelli et al., 2016). In this study, to further support our hypothesis, we exploited GWAS meta-analysis data from the COVID-19 Host Genetics Initiative (COVID-19 Host Genetics Initiative, 2020) and performed an in-depth genetic analysis of chromosome 21 using summary statistics where common variants at this chromosome were associated with severe COVID-19 at the genome-wide significance level (p ≤ 5 × 10−8). Using the cohort of 908,494 subjects with European origins, we found five SNPs at the TMPRSS2/MX1 locus showing suggestive association with the disease. All five SNPs replicated the association in two independent cohorts of Asian subjects, whereas two SNPs confirmed the association in African and one SNP in the Italian cohort. Significant eQTLs signals were found for the MX1 gene in blood.

Results

TMPRSS2/MX1 locus is associated with severe COVID-19

To prove that common variants at TMPRSS2/MX1 (21q22.3) locus may affect the susceptibility to severe COVID-19 onset, we analyzed the summary statistics of a large available GWAS dataset released by the COVID-19 Host Genetics Initiative (COVID-19 Host Genetics Initiative, 2020). The data set includes 6,406 hospitalized cases and 902,088 controls with European ancestry (Table S1). A region on chromosome 21 appears to be significantly associated with severe COVID-19 at the genome-wide level (https://www.covid19hg.org/results/) as also demonstrated in a recently published GWAS study (Pairo-Castineira et al., 2021). To investigate whether more than one association signals may exist at chromosome 21, we selected 74 SNPs showing a p ≤ 1 × 10−5 and we identified 3 independent loci among them (Table S2). The most significant signal was represented by rs13050728 (p = 2.76 × 10−12, OR = 0.83, Figure 1A) that maps within the INFRA2 gene. The other two signals showed a suggestive significance level (p ≤ 1 × 10−5) and were tagged by rs111783124 (p = 2.39 × 10−6, OR = 1.17, Figure 1B) and rs3787946 (p = 2.73 × 10−6, OR = 0.87, Figure 1C), respectively. The rs3787946 maps in an intronic region of TMPRSS2 and the first closest gene was MX1 (Figure 1C); herein, we named this locus as “TMPRSS2/MX1”. An in-depth inspection of the TMPRSS2/MX1 locus showed that 13 SNPs were in linkage disequilibrium (LD) with the lead rs3787946 (r2 > 0.8, Table 1) and that the 5 most significant SNPs (p values ranging from 2.7 × 10−6 to 5.8 × 10−6, Table 1) were in strong LD with each other (r2≥0.90, Figure S1). The other 9 SNPs showed an LD with the lead SNP rs3787946 ranging from 0.8 to 0.9 and p values ranging from 6 × 10−4 to 0.04 (Table 1). We then sought to replicate the associations of the 14 SNPs in three independent cohorts of cases and controls of GenOMMIC GWAS (Pairo-Castineira et al., 2021) with non-European ancestry. All the 11 available SNPs replicated in the east asian (EAS) population; the top five SNPs replicated in the South Asian (SAS) ancestry population, whereas two of five SNPs in the African (AFR) one (Table 1). By using the TaqMan assay, we typed the rs12329760 variant in samples from 226 hospitalized COVID-19 patients (Table S3) and 1848 controls from Southern Italy collected in our Institute. An additional Italian cohort of 1915 controls and 770 cases, typed for rs12329760 by whole-exome sequencing, was obtained from the Network for Italian Genomes (NIG) database (Daga et al., 2021). After combining the two cohorts, we confirmed the minor allele as a protective factor against the aggressive form of the disease (Table 2, ORallele = 0.89, Pallele = 0.07; ORdominant = 0.57, p = 0.01; ORCCvsTT = 0.57, p = 0.01). The results of our case-control study suggest that the protective effect against the severity of COVID-19 is mainly due to the TT genotype.
Figure 1

Regional association plots of the SNPs at three independent association signals of chromosome 21

Plots were generated using LocusZoom. Y axes represent the significance of association (−log10 transformed p values) and the recombination rate. SNPs are color-coded based on pairwise linkage disequilibrium (r2) with indicated lead SNPs: rs13050728 (A), rs111783124 (B) and rs3787946 (C).

Table 1

Associations of SNPs at TMPRSS2/MX1 risk locus in linkage disequilibrium with the lead rs3787946 in different populations and prioritization scores

RS numberEAOAMAFr2ORP_EURORP_EASORP_SASORP_AFRaRegion scoreaTSS scorebPredicted functionbScorecCombined score
rs3787946CG0.231.000.872.73 × 10−60.630.0260.710.020.740.070.160.29INTRONIC26
rs9983330GA0.230.910.883.12 × 10−60.540.0040.730.040.790.160.310.64REGULATORY426
rs12329760TC0.240.900.883.13 × 10−60.640.0290.760.080.780.140.320.41MISSENSE723
rs2298661AC0.230.990.884.51 × 10−60.630.0300.670.010.600.010.180.35INTRONIC29
rs9985159TC0.230.980.885.80 × 10−60.610.0180.750.060.980.890.160.46INTRONIC215
rs2298660TC0.200.820.880.001NANANANANANA0.120.28INTRONIC24
rs7364088AG0.260.840.910.002NANANANANANA0.190.23INTRONIC26
rs2298663TC0.250.871.080.0051.490.0521.120.400.940.660.260.37REGULATORY415
rs2094881CT0.250.871.080.0051.470.0581.100.470.930.600.290.26REGULATORY413
rs8131649TC0.250.850.920.0070.640.0350.900.461.010.930.260.35REGULATORY412
rs8134203TC0.260.851.080.0071.490.0581.090.540.910.500.260.41REGULATORY417
rs8134216TC0.260.851.080.0071.540.0381.110.430.910.490.280.4REGULATORY419
rs2104810AG0.260.851.080.0081.540.0401.100.470.900.480.230.35REGULATORY411
rs8131648CT0.260.851.070.036NANANANANANA0.330.42REGULATORY426

In bold the SNPs that replicated in at least one cohort.

EA: Effect Allele; OA: Other Allele; EUR: European; EAS: East Asian; SAS: South Asian; AFR: African; ITA: Italian; MAF: minor allele frequency; OR: odds ratio.

Scores from GWAVA predictor tool.

Scores from CADD predictor tool.

GWAVA and CADD scores were ranked from the smallest to largest and the obtained values were summed.

Table 2

Association of rs12329760 SNP with severe COVID-19 in Italian population

GenotypeSI casesn = 226
SI controlsn = 1848
NIG casesn = 770
NIG controlsn = 1915
All casesn = 996
All controlsn = 3763
PSIOR (CI: 95%)PNIGOR (CI: 95%)PAllOR (CI: 95%)
n%n%n%n%n%n%

CC16472.6127468.953269.1128967.369669.9256368.1
CT5725.249726.922028.655428.927727.8105127.90.470.89 (0.64–1.22)0.680.96 (0.79–1.15)0.710.97 (0.83–1.13)
TT52.2774.2182.3723.8232.31494.00.140.50 (0.20–1.26)0.060.60 (0.35–1.02)0.010.57 (0.36–0.89)

Allele

C38585.2304582.4128483.4313281.8166983.8617782.1
T6714.865117.625616.669818.232316.2134917.90.140.81 (0.62–1.07)0.160.89 (0.76–1.04)0.070.89 (0.78–1.01)

Dominant

CC/CT22197.8177195.875297.7184396.297397.7361496.0
TT52.2774.2182.3723.8232.31494.00.150.52 (0.20–1.30)0.060.61 (0.36–1.03)0.010.57 (0.37–0.89)

Recessive

CC15970.4127468.953269.1128967.369169.4256368.1
CT/TT6227.457431.123830.962632.730030.1120031.90.260.84 (0.61–1.14)0.370.92 (0.76–1.10)0.280.92 (0.79–1.07)

NIG, Network for Italian Genomes; OR, odds ratio; CI, confidence interval; SI, Southern Italy.

In bold are highlighted the statistically significant results.

Regional association plots of the SNPs at three independent association signals of chromosome 21 Plots were generated using LocusZoom. Y axes represent the significance of association (−log10 transformed p values) and the recombination rate. SNPs are color-coded based on pairwise linkage disequilibrium (r2) with indicated lead SNPs: rs13050728 (A), rs111783124 (B) and rs3787946 (C). Associations of SNPs at TMPRSS2/MX1 risk locus in linkage disequilibrium with the lead rs3787946 in different populations and prioritization scores In bold the SNPs that replicated in at least one cohort. EA: Effect Allele; OA: Other Allele; EUR: European; EAS: East Asian; SAS: South Asian; AFR: African; ITA: Italian; MAF: minor allele frequency; OR: odds ratio. Scores from GWAVA predictor tool. Scores from CADD predictor tool. GWAVA and CADD scores were ranked from the smallest to largest and the obtained values were summed. Association of rs12329760 SNP with severe COVID-19 in Italian population NIG, Network for Italian Genomes; OR, odds ratio; CI, confidence interval; SI, Southern Italy. In bold are highlighted the statistically significant results.

SNPs at TMPRSS2/MX1 locus are enriched in regulatory regions active in the thymus

We tested if the 14 SNPs (Table 1) and their proxy SNPs (r2 > 0.8) were significantly over-represented in active enhancers and promoters in multiple cell types and tissues by using HaploReg v4.1. These SNPs were enriched in the regulatory regions of several tissues (Table S4) but the best enrichment was found in induced pluripotent stem cells and thymus (Figure 2A).
Figure 2

Enrichment of SNPs in regulatory regions and eQTL analyses

The statistically significant fold enrichments (p < 0.05 after Bonferroni correction) of SNPs in regulatory DNA regions active in different tissues are shown (A). eQTL violin plots between genotypes of rs3787946 (B) and rs3787946 (C) with MX1 and TMPRSS2 expression from the Genotype-Tissue Expression (GTEx). The significance threshold adjusted for multiple comparisons is equal to 0.000055.

Enrichment of SNPs in regulatory regions and eQTL analyses The statistically significant fold enrichments (p < 0.05 after Bonferroni correction) of SNPs in regulatory DNA regions active in different tissues are shown (A). eQTL violin plots between genotypes of rs3787946 (B) and rs3787946 (C) with MX1 and TMPRSS2 expression from the Genotype-Tissue Expression (GTEx). The significance threshold adjusted for multiple comparisons is equal to 0.000055.

Functional role of the most significant SNPs at TMPRSS2/MX1 locus

We then investigated the predicted functional role of the 14 SNPs by GWAVA and CADD tools. We found that two of the five most significant SNPs, i.e. rs9983330 and rs12329760, showed the first (combined score = 26) and second (combined score = 23) most significant score (Table 1). The rs12329760 was classified as a coding variant (p.Val197Met) localized in the exon 6 of the TMPRSS2 gene and was predicted to be pathogenic (PolyPhen-2 = probably damaging and SIFT = deleterious).

The most significant disease-associated SNPs are eQTLs for MX1 in blood

We verified if the top five SNPs (Table 1) might cause gene expression alterations interrogating the GTEx portal for all the common variants within TMPRSS2/MX1 locus. We found that all the top five SNPs had eQTL signals for MX1 exclusively in blood tissue. Particularly, the minor alleles of these SNPs correlated with higher expression of MX1 compared to the major alleles (Figures 2B and S2A). Of note, all the other SNPs, except for rs2298660, did not have eQTL signals for MX1 in the blood (Table S5). The two SNPs rs12329760 and rs2298660 were confirmed as eQTLs for MX1 in the blood (p = 1.79 × 10−6 and 2.8 × 10−6, minor alleles correlated with a higher expression compared to the major alleles) by interrogation of another independent publicly available data set (Westra et al., 2013). TMPRSS2 is highly expressed in lung (Russo et al., 2020), so we investigated if the top five SNPs were eQTLs for TMPRSS2 in lung tissues at a nominally statistically significant level (p ≤ 0.05). We found that the minor alleles of four out of five SNPs correlated with lower expression of TMPRSS2 compared to the major alleles (Figures 2C and S2B). Notably, rs12329760 is also an eQTL for TMPRSS2 in osteoblasts treated with dexamethasone (Grundberg et al., 2011).

Discussion

Despite the substantial advances made in recent months in the field of SARS-CoV-2 infection, the major question remains about the identification of the factors that modulate the variable clinical spectrum of COVID-19. Host genetic risk factors are emerging as a potential explanation for the clinical heterogeneity of COVID-19 and are also crucial to find new druggable therapeutic targets (Asselta et al., 2020; Beck and Aksentijevich, 2020; Benetti et al., 2020; Pairo-Castineira et al., 2021; Singh et al., 2020). The main host cell entry factors of SARS-CoV-2 are ACE2 and TMPRSS2 (Asselta et al., 2020; Benetti et al., 2020). The spike (S) glycoprotein of the virus binds to the ACE2 making it essential for the entry of the virus into the host cell. S-protein priming by the serine protease TMPRSS2 allows the fusion of viral and cellular membranes, resulting in virus entry and replication in the host cells (Singh et al., 2020). TMPRSS2 is emerging as a host cell factor that is critical for SARS-CoV-2 infection (Hoffmann et al., 2020b). In our previous study, we hypothesized that common variants at chromosome 21, driving TMPRSS2 and MX1 expression, might have a mild-to-moderate effect on the susceptibility to SARS-CoV-2 infection. Particularly, genetic variants associated with reduced TMPRSS2 and elevated MX1 expression might confer less individual susceptibility to SARS-CoV-2 infection and favor a better outcome (Russo et al., 2020). Here, to further support our hypothesis, we exploited GWAS data of a cohort of 908,494 subjects with European origins from the COVID-19 Host Genetics Initiative (COVID-19 Host Genetics Initiative, 2020) and performed an in-depth genetic analysis of chromosome 21. We identified five common variants (rs3787946, rs9983330, rs12329760, rs2298661, and rs9985159) at locus 21q22.3 within TMPRSS2 and near the MX1 gene that showed suggestive associations with severe COVID-19. In particular, we found that the alleles with minor frequency were less recurrent among hospitalized patients when compared to the control individuals, suggesting their protective role against the progression of the disease. Interestingly, all five SNPs were replicated in two cohorts of Asian origin, whereas two SNPs replicated in a case series of African ancestry. Additionally, we replicated the association of the rs12329760 SNP in an independent case-control cohort of Italian origin. As “proof of concept”, the rs12329760 SNP was also detected in recent studies (Hou et al., 2020; Vargas-Alarcon et al., 2020). It was demonstrated that the SNP, in addition to its eQTL role, decreased the stability of the protein, which might impede viral entry (Vishnubhotla et al., 2020); moreover, in silico analysis demonstrated that it created a de novo pocket protein (Paniri et al., 2020). These results confirm 21q22.3 as a novel susceptibility locus to unfavorable outcome of COVID-19. Furthermore, molecular mechanisms underlying this genetic predisposition may be common among individuals with different ethnicity. The results from our enrichment analysis for regulatory genomic regions suggested that the identified SNPs and other proxy SNPs located at 21q22.3 locus can be associated with different outcomes of COVID-19 by altering DNA elements that regulate the transcription of MX1 and likely of other genes relevant to the thymus functions. The thymus plays a significant role in the regulation of adaptive immune responses. The effect of aging on the thymus and immune senescence is well established, and the resulting inflammaging is found to be implicated in the development of many chronic diseases (Gunes et al., 2020; Kellogg and Equils, 2020). Both aging and diseases of inflammaging are associated with severe COVID-19, and a dysfunctional thymus may be implicated in the unfavorable outcome of disease (Gunes et al., 2020; Kellogg and Equils, 2020). Of note, MX1 plays an important role in the thymus as part of the innate antiviral immune response. Indeed, it is exclusively expressed after engagement of the type I interferon receptor by interferon-α/β in normal fetal and post-natal human thymus, but not in the periphery. The highest level of MX1 is properly found in mature thymocytes (Colantonio et al., 2011). The five SNPs here identified had eQTL signals for MX1 exclusively in blood tissue. Particularly, the minor allele of these SNPs correlated with higher expression of MX1 and associated with a minor risk of developing severe COVID-19. These results support the evidence that MX1 can play a relevant role in determining less severe forms of disease and are in line with a recent study that suggests MX1 as an antiviral effector against SARS-CoV-2 (Bizzotto et al., 2020). Indeed, the expression of MX1 was found to be high in SARS-CoV-2 positive subjects, negatively correlated with age, and independently associated with increased viral load (Bizzotto et al., 2020). MX1 is part of the antiviral response induced by type I and III interferons (Zav'yalov et al., 2019). Inactivating mutations in genes belonging to type I interferon pathway and the consequently decreased levels of proteins have been shown to occur in patients with severe COVID-19 (Zhang et al., 2020). Of note, within the region on chromosome 21, significantly associated with severe COVID-19 at the genome-wide level, the most significant signal was represented by rs13050728 that maps within the INFRA2 gene. Particularly, INFRA2 gene encodes for the type I membrane protein that forms the interferon-α/β receptor, involved in the canonical host antiviral signaling mediators (Duncan et al., 2015), so associated with interferon signaling like MX1. The SNP rs13050728 was previously identified as lead variant from the meta-analysis of overlapping SNPs between GenOMICC, The COVID-19 Host Genetics Initiative and 23andMe studies and its allele C was reported to reduce the odds of severe COVID-19 as associated with an increased expression of IFNAR2 (Pairo-Castineira et al., 2021). These findings, along with ours, further strength the protective role of IFN pathway against severe COVID-19. We also report that the minor allele of four of the top five SNPs might reduce the expression of TMPRSS2 in lung tissues. In particular, the rs12329760 coding variant (p.Val197Met) is predicted to decrease the TMPRSS2 protein stability and ACE2 binding, thus decreasing virus entry into the cells (Vishnubhotla et al., 2020). Of note, this variant was recently found to be less frequent among Chinese patients with critical COVID-19 disease (Wang et al., 2020). Additionally, it correlates with lower expression of TMPRSS2 in osteoblast treated with dexamethasone (Grundberg et al., 2011), a drug currently used to inhibit an excessive inflammation response (Group et al., 2020). Together, these data suggest that even the functions of TMPRSS2 may be affected by the occurrence of protective variants against severe COVID-19. Finally, we want to point out that our findings highlight the effectiveness of investigating other independent (putative) risk loci, when they do not pass genome-wide significance levels. These loci, usually overlooked in extensive meta-analysis and multi-cohorts efforts, might indeed contain important genetic variants associated with severe COVID-19 and map genes relevant to the pathogenesis of this disease. We then encourage post-GWAS genetic (re)analyses using multiple data sources to unravel novel COVID-19 risk loci and possible insights on the underlying biology. In conclusion, our results provide evidence that common variants, regulating the expression of MX1, can predispose to the risk of developing severe COVID-19. Unraveling the role of regulatory variants at the TMPRSS2/MX1 locus could represent an important starting point for the treatment of COVID-19.

Limitations of the study

The data on eQTLs related to TMPRSS2 must be interpreted with caution as these eQTL signals in the lung (p = 0.019) do not pass the GTEx significance threshold adjusted for multiple comparisons (0.000055). Additional studies are required to further verify the role of genetic variants at TMPRSS2/MX1 locus in modulating the TMPRSS2 expression. Furthermore, the statistical approach adopted in this study did not include multivariate analyses to take into account confounding factors. Although this limitation does not affect the robustness of the presented genetic associations as replicated in multiple independent cohorts, we believe that future studies will help to better define the effect of genetic variants at TMPRSS2/MX1 locus on the clinical subgroups of COVID-19 disease; for instance, performing association analyses on patients stratified by disease aggressiveness or controlled for comorbidities in larger cohorts.

Methods

All methods can be found in the accompanying transparent methods supplemental file.

Resource availability

Lead contact

Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Prof. Mario Capasso, mario.capasso@unina.it.

Material availability

This study did not generate nor use any new or unique reagents.

Data and code availability

Manhattan plot and QQ plot of the results from the large GWAS “The COVID-19 Host Genetics Initiative website” are available at the website (https://www.covid19hg.org/results/). The 770 hospitalized COVID-19 cases and 1915 controls typed for rs12329760 by whole-exome sequencing were retrieved from the web database Network for Italian Genomes (NIG) available at the website (http://nigdb.cineca.it/index.php). Prediction of the functional impact of 14 SNPs at TMPRSS2/MX1 locus was assessed by Genome Wide Annotation of VAriants (GWAVA) tool available at the website (https://www.sanger.ac.uk/sanger/StatGen_Gwava) and by Combined Annotation Dependent Depletion (CADD) tool at (https://cadd.gs.washington.edu/). The Blood eQTL Browser is available at (https://www.genenetwork.nl/bloodeqtlbrowser/).
  30 in total

1.  GertJan B. van Ommen 28 September 1947-7 November 2020.

Authors:  Mary Rice
Journal:  Eur J Hum Genet       Date:  2020-12-16       Impact factor: 4.246

2.  The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.

Authors: 
Journal:  Eur J Hum Genet       Date:  2020-05-13       Impact factor: 4.246

Review 3.  Ventilation of coronavirus disease 2019 patients.

Authors:  Giacomo Grasselli; Emanuele Cattaneo; Vittorio Scaravilli
Journal:  Curr Opin Crit Care       Date:  2021-02-01       Impact factor: 3.687

4.  Genetic mechanisms of critical illness in COVID-19.

Authors:  Erola Pairo-Castineira; Sara Clohisey; Lucija Klaric; Andrew D Bretherick; Konrad Rawlik; Dorota Pasko; Susan Walker; Nick Parkinson; Max Head Fourman; Clark D Russell; James Furniss; Anne Richmond; Elvina Gountouna; Nicola Wrobel; David Harrison; Bo Wang; Yang Wu; Alison Meynert; Fiona Griffiths; Wilna Oosthuyzen; Athanasios Kousathanas; Loukas Moutsianas; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Graeme Grimes; Rupert Beale; Jonathan Millar; Barbara Shih; Sean Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Jian Yang; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Paul Klenerman; Lance Turtle; Antonia Ho; Shona C Moore; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Danny McAuley; Hugh Montgomery; Timothy Walsh; Alexandre C Pereira; Alessandra Renieri; Xia Shen; Chris P Ponting; Angie Fawkes; Albert Tenesa; Mark Caulfield; Richard Scott; Kathy Rowan; Lee Murphy; Peter J M Openshaw; Malcolm G Semple; Andrew Law; Veronique Vitart; James F Wilson; J Kenneth Baillie
Journal:  Nature       Date:  2020-12-11       Impact factor: 69.504

5.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure.

Authors:  David Ellinghaus; Frauke Degenhardt; Luis Bujanda; Maria Buti; Agustín Albillos; Pietro Invernizzi; Javier Fernández; Daniele Prati; Guido Baselli; Rosanna Asselta; Marit M Grimsrud; Chiara Milani; Fátima Aziz; Jan Kässens; Sandra May; Mareike Wendorff; Lars Wienbrandt; Florian Uellendahl-Werth; Tenghao Zheng; Xiaoli Yi; Raúl de Pablo; Adolfo G Chercoles; Adriana Palom; Alba-Estela Garcia-Fernandez; Francisco Rodriguez-Frias; Alberto Zanella; Alessandra Bandera; Alessandro Protti; Alessio Aghemo; Ana Lleo; Andrea Biondi; Andrea Caballero-Garralda; Andrea Gori; Anja Tanck; Anna Carreras Nolla; Anna Latiano; Anna Ludovica Fracanzani; Anna Peschuck; Antonio Julià; Antonio Pesenti; Antonio Voza; David Jiménez; Beatriz Mateos; Beatriz Nafria Jimenez; Carmen Quereda; Cinzia Paccapelo; Christoph Gassner; Claudio Angelini; Cristina Cea; Aurora Solier; David Pestaña; Eduardo Muñiz-Diaz; Elena Sandoval; Elvezia M Paraboschi; Enrique Navas; Félix García Sánchez; Ferruccio Ceriotti; Filippo Martinelli-Boneschi; Flora Peyvandi; Francesco Blasi; Luis Téllez; Albert Blanco-Grau; Georg Hemmrich-Stanisak; Giacomo Grasselli; Giorgio Costantino; Giulia Cardamone; Giuseppe Foti; Serena Aneli; Hayato Kurihara; Hesham ElAbd; Ilaria My; Iván Galván-Femenia; Javier Martín; Jeanette Erdmann; Jose Ferrusquía-Acosta; Koldo Garcia-Etxebarria; Laura Izquierdo-Sanchez; Laura R Bettini; Lauro Sumoy; Leonardo Terranova; Leticia Moreira; Luigi Santoro; Luigia Scudeller; Francisco Mesonero; Luisa Roade; Malte C Rühlemann; Marco Schaefer; Maria Carrabba; Mar Riveiro-Barciela; Maria E Figuera Basso; Maria G Valsecchi; María Hernandez-Tejero; Marialbert Acosta-Herrera; Mariella D'Angiò; Marina Baldini; Marina Cazzaniga; Martin Schulzky; Maurizio Cecconi; Michael Wittig; Michele Ciccarelli; Miguel Rodríguez-Gandía; Monica Bocciolone; Monica Miozzo; Nicola Montano; Nicole Braun; Nicoletta Sacchi; Nilda Martínez; Onur Özer; Orazio Palmieri; Paola Faverio; Paoletta Preatoni; Paolo Bonfanti; Paolo Omodei; Paolo Tentorio; Pedro Castro; Pedro M Rodrigues; Aaron Blandino Ortiz; Rafael de Cid; Ricard Ferrer; Roberta Gualtierotti; Rosa Nieto; Siegfried Goerg; Salvatore Badalamenti; Sara Marsal; Giuseppe Matullo; Serena Pelusi; Simonas Juzenas; Stefano Aliberti; Valter Monzani; Victor Moreno; Tanja Wesse; Tobias L Lenz; Tomas Pumarola; Valeria Rimoldi; Silvano Bosari; Wolfgang Albrecht; Wolfgang Peter; Manuel Romero-Gómez; Mauro D'Amato; Stefano Duga; Jesus M Banales; Johannes R Hov; Trine Folseraas; Luca Valenti; Andre Franke; Tom H Karlsen
Journal:  N Engl J Med       Date:  2020-06-17       Impact factor: 91.245

6.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.

Authors:  Shutoku Matsuyama; Naganori Nao; Kazuya Shirato; Miyuki Kawase; Shinji Saito; Ikuyo Takayama; Noriyo Nagata; Tsuyoshi Sekizuka; Hiroshi Katoh; Fumihiro Kato; Masafumi Sakata; Maino Tahara; Satoshi Kutsuna; Norio Ohmagari; Makoto Kuroda; Tadaki Suzuki; Tsutomu Kageyama; Makoto Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-12       Impact factor: 11.205

7.  Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility.

Authors:  Fang Wang; Shujia Huang; Rongsui Gao; Yuwen Zhou; Changxiang Lai; Zhichao Li; Wenjie Xian; Xiaobo Qian; Zhiyu Li; Yushan Huang; Qiyuan Tang; Panhong Liu; Ruikun Chen; Rong Liu; Xuan Li; Xin Tong; Xuan Zhou; Yong Bai; Gang Duan; Tao Zhang; Xun Xu; Jian Wang; Huanming Yang; Siyang Liu; Qing He; Xin Jin; Lei Liu
Journal:  Cell Discov       Date:  2020-11-10       Impact factor: 10.849

8.  SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients.

Authors:  Juan Bizzotto; Pablo Sanchis; Mercedes Abbate; Sofía Lage-Vickers; Rosario Lavignolle; Ayelén Toro; Santiago Olszevicki; Agustina Sabater; Florencia Cascardo; Elba Vazquez; Javier Cotignola; Geraldine Gueron
Journal:  iScience       Date:  2020-09-23

Review 9.  Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity.

Authors:  Cleo Anastassopoulou; Zoi Gkizarioti; George P Patrinos; Athanasios Tsakris
Journal:  Hum Genomics       Date:  2020-10-22       Impact factor: 4.639

Review 10.  ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.

Authors:  HariOm Singh; Ranjana Choudhari; Vijay Nema; Abdul Arif Khan
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848

View more
  19 in total

Review 1.  Effects of selected inherited factors on susceptibility to SARS-CoV-2 infection and COVID-19 progression.

Authors:  J A Hubacek
Journal:  Physiol Res       Date:  2021-12-16       Impact factor: 1.881

2.  Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women.

Authors:  Maria Monticelli; Bruno Hay Mele; Elisa Benetti; Chiara Fallerini; Margherita Baldassarri; Simone Furini; Elisa Frullanti; Francesca Mari; Giuseppina Andreotti; Maria Vittoria Cubellis; Alessandra Renieri
Journal:  Genes (Basel)       Date:  2021-04-19       Impact factor: 4.096

3.  Host polymorphisms and COVID-19 infection.

Authors:  Joris R Delanghe; Marijn M Speeckaert
Journal:  Adv Clin Chem       Date:  2021-08-23       Impact factor: 5.394

4.  Host genetic factors of COVID-19 susceptibility and disease severity in a Thai population.

Authors:  Monpat Chamnanphon; Monnat Pongpanich; Thitima Benjachat Suttichet; Watsamon Jantarabenjakul; Pattama Torvorapanit; Opass Putcharoen; Pimpayao Sodsai; Chureerat Phokaew; Nattiya Hirankarn; Pajaree Chariyavilaskul; Vorasuk Shotelersuk
Journal:  J Hum Genet       Date:  2022-01-11       Impact factor: 3.755

5.  In Silico Molecular Characterization of Human TMPRSS2 Protease Polymorphic Variants and Associated SARS-CoV-2 Susceptibility.

Authors:  Mohd Zulkifli Salleh; Zakuan Zainy Deris
Journal:  Life (Basel)       Date:  2022-02-03

6.  Association of Asthma and Rhinitis with Epigenetics of Coronavirus Related Genes.

Authors:  Aniruddha Rathod; Rutu Rathod; Hongmei Zhang; Parnian Kheirkhah Rahimabad; Wilfried Karmaus; Hasan Arshad
Journal:  Epigenet Insights       Date:  2021-09-29

7.  Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.

Authors:  Jingwei Li; Yali Wang; Yong Liu; Ziqu Zhang; Yuyun Zhai; Yan Dai; Zijian Wu; Xiang Nie; Lunfei Du
Journal:  Eur J Med Res       Date:  2022-02-22       Impact factor: 2.175

Review 8.  The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic.

Authors:  Maria Karoliny da Silva Torres; Carlos David Araújo Bichara; Maria de Nazaré do Socorro de Almeida; Mariana Cayres Vallinoto; Maria Alice Freitas Queiroz; Izaura Maria Vieira Cayres Vallinoto; Eduardo José Melo Dos Santos; Carlos Alberto Marques de Carvalho; Antonio Carlos R Vallinoto
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

9.  Identification of SARS-CoV-2 Proteins from Nasopharyngeal Swabs Probed by Multiple Reaction Monitoring Tandem Mass Spectrometry.

Authors:  Gabriella Pinto; Anna Illiano; Veronica Ferrucci; Fabrizio Quarantelli; Carolina Fontanarosa; Roberto Siciliano; Carmela Di Domenico; Barbara Izzo; Piero Pucci; Gennaro Marino; Massimo Zollo; Angela Amoresano
Journal:  ACS Omega       Date:  2021-12-07

10.  Regulatory Noncoding and Predicted Pathogenic Coding Variants of CCR5 Predispose to Severe COVID-19.

Authors:  Sueva Cantalupo; Vito Alessandro Lasorsa; Roberta Russo; Immacolata Andolfo; Giuseppe D'Alterio; Barbara Eleni Rosato; Giulia Frisso; Pasquale Abete; Gian Marco Cassese; Giuseppe Servillo; Ivan Gentile; Carmelo Piscopo; Matteo Della Monica; Giuseppe Fiorentino; Giuseppe Russo; Pellegrino Cerino; Carlo Buonerba; Biancamaria Pierri; Massimo Zollo; Achille Iolascon; Mario Capasso
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.